Christopher Kroeger Sells 13,980 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CEO Christopher Kroeger sold 13,980 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $30.11, for a total value of $420,937.80. Following the transaction, the chief executive officer owned 1,512,329 shares of the company’s stock, valued at $45,536,226.19. The trade was a 0.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maplight Therapeutics Price Performance

Shares of MPLT opened at $30.30 on Wednesday. The business’s 50-day moving average is $23.54. The stock has a market cap of $1.29 billion and a PE ratio of -0.76. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, research analysts predict that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Hedge Funds Weigh In On Maplight Therapeutics

Large investors have recently modified their holdings of the company. Walleye Capital LLC purchased a new stake in Maplight Therapeutics in the fourth quarter worth approximately $205,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $172,000. Police & Firemen s Retirement System of New Jersey bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $70,000. Bank of New York Mellon Corp grew its position in Maplight Therapeutics by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock valued at $802,000 after acquiring an additional 3,608 shares during the last quarter. Finally, 5AM Venture Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $16,687,000.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on MPLT shares. Weiss Ratings started coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Needham & Company LLC began coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target on the stock. TD Cowen began coverage on Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating on the stock. HC Wainwright began coverage on Maplight Therapeutics in a report on Monday, May 4th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Canaccord Genuity Group began coverage on Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.43.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.